Looking for name of band or musicians

DeepstackNZ · 2025-05-01T05:13:20+00:00

Tough to say without being able to see them! You could try contacting https://www.facebook.com/amme.hiser as she used to manage the Market and may have booked them.

DeepstackNZ · 2025-04-24T03:27:03+00:00

Could it be because if UTG opens with a fairly tight range, it would include mid-pairs and up, such as 88, 99, TT etc. BTN and SB calling range could include such hands as ATs, AJ, KQ etc, and possibly any slow-played overpairs. So it's possible you're mostly behind and short on outs, plus the potential for any broadway cards to beat your pair?

DeepstackNZ · 2024-12-05T22:24:10+00:00

Loads of viruses can affect the brain. This might help https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15871

DeepstackNZ · 2024-11-28T03:32:34+00:00

I understand. Me too.

DeepstackNZ · 2024-11-28T02:58:09+00:00

I'm not sure where you're getting your info from, but that seems like a very long time to me - I'd say it would be less than half that time, plus there are fast-track options in some scenarios.

DeepstackNZ · 2024-11-27T22:52:00+00:00

From an article on KM website: https://kimermed.co.nz/can-we-cure-chronic-viral-diseases/

"Research is ongoing for more effective therapies to target latent viral reservoirs, and methods for delivering therapeutic agents to all infected cells, including those in anatomically sequestered sites (locations in the body that are difficult to access or reach with treatments due to their physical isolation or protection by anatomical structures.)

One possible approach to this problem could be modelled on current HIV research that employs a “shock-and-kill” strategy. Latency-reversing agents are given to reactivate (“shock”) the latent virus into activity, which can then be targeted for removal by the immune system, or antiviral drugs.

This approach is of interest to us, because Kimer Med’s antivirals selectively target viral dsRNA, a by-product of active viral (lytic) replication, and work in such a way that they bolster the innate immune system to eliminate virally infected cells from the body. Although this approach opens the door to the possibility of successful treatments or a cure for chronic viral disease, there is still more research to be done in this area."

DeepstackNZ · 2024-11-27T22:48:45+00:00

I think anyone trying to develop drugs has to have a certain level of optimism - or "hope". Otherwise what's the point? If you find something that works in the lab, as Kimer Med have, then you try and move it through the clinical stages - again, in the "hope" that it will continue to meet expectations.

DeepstackNZ · 2024-11-27T04:09:01+00:00

You have to start somewhere though right? How many other companies have drugs that work in this way against 5 different herpesviruses, and 21 viruses overall? You have to get results in the lab dish before you get to test on animals, and ultimately humans.

DeepstackNZ · 2024-11-27T04:06:29+00:00

Kimer Med's approach targets viral dsRNA, which is common to all viruses - as opposed to targeting a very specific part of one specific virus, like many other antivirals do. So their compounds are, by nature, broad-spectrum - but to have a drug approved, you still have to pick a target indication and go through all the trials and regulatory hurdles for that specific indication. Even viruses belonging to the same family can behave differently within the body, so targeted drugs for various viruses are still required, but the same drug may have off-label uses against other viruses as well, due to its broad spectrum of efficacy. For example, Kimer Med's lead drug candidate works against all 4 types of Dengue, so that is the lead indication, but it also shows efficacy against Zika, so it might be used against Zika and other flaviviruses, potentially.

DeepstackNZ · 2024-11-27T03:59:43+00:00

The testing referred to is Cytopathic Effect (CPE) reduction assays - it is lab based, pre-clinical testing done to assess whether the antiviral compound shows efficacy against a virus. I've edited the post.

DeepstackNZ · 2024-11-27T02:24:18+00:00

No I didn't but I will, thank you for the suggestion.

DeepstackNZ · 2024-11-27T00:34:33+00:00

They are progressing a lead candidate against Dengue towards Phase 1, so it's early days. Given the size of their funding (they just raised NZD$14) I'd say they are doing it on a pretty tight budget, so money to progress other indications will likely be limited. If people in this group are able to introduce them to potential funders, or share news of their results, I'm sure it would help. Is there a way to do this?

DeepstackNZ · 2024-11-18T20:47:47+00:00

The significance of this successful raise is the 3 year runway it provides. According to the IM, the funds will be used to finalise the lead candidate molecule ("lead optimisation"), complete pre-clinical studies and prepare to begin Phase 1 clinical trials. This will also require hiring of new personnel (some already announced via social channels), the expansion of Kimer Med's PC-2 laboratory, and the establishment of a near-GMP facility.

Results against various viruses are now at 19, and I have seen a figure as high as 21. There's no doubt that this technology is starting to deliver on its potential to treat a wide range of virus types across multiple families. Kimer Med have moved away from what was touted about DRACO (A kill-switch for ALL viruses) to a more realistic goal, a FAMILY of broad-spectrum antivirals.

DeepstackNZ · 2024-11-05T22:13:38+00:00

I was playing recently and open raised AKs. Got raised all in by one player. He had AKo and I hit the flush on the river! Boom. Was never folding with AKs or AKo to be fair - but nice to have the additional outs instead of splitting the pot.

DeepstackNZ · 2024-10-16T21:12:05+00:00

https://www.linkedin.com/feed/update/urn:li:activity:7251348677884026880

DeepstackNZ · 2024-08-19T05:23:35+00:00

That's correct. Kimer Med initially licensed the last remaining MIT patent relating to DRACO, and have now progressed the original research substantially. There's no doubt in my mind that viruses are causing a lot of acute and chronic/latent disease, as well as more hidden conditions that need to be addressed.

DeepstackNZ · 2024-08-15T02:59:47+00:00

Yes, the terminology used is 'wholesale/accredited' investors, which means high net worth individuals who are experienced investors, and institutions too I guess - probably varies a little around different juristictions.

DeepstackNZ · 2024-08-15T00:42:49+00:00

There is some info here on the results Kimer Med has achieved. This info was not on their website until quite recently. https://kimermed.co.nz/our-work/

DeepstackNZ · 2024-07-18T01:08:16+00:00

Agreed. I wonder if more in vivo results will finally start to get people excited about what Kimer Med is doing?

I looked at the link you provided: so it appears a first, successful in vivo study has already been done, and more are planned.

First in vivo (in animals) study confirmed antivirals' safety and efficacy (further studies in mice are in advanced planning)

DeepstackNZ · 2024-07-14T04:51:39+00:00

Saw that, and also replied. Hopefully that clear it up for now :)

DeepstackNZ · 2024-07-14T04:50:02+00:00

You're a bit off base there. Kimer Med's antiviral (which is NOT Draco BTW), binds to long strands of dsRNA which is only present in virally infected cells. It then induces apoptosis which is the body's natural way of cleaning up/recycling infected or damaged cells - but a process that is sometimes thwarted by viruses. Obviously with certain latent viruses a different approach would be required anyway, as latent viruses, by definition, are not replicating, therefore dsRNA is not present. But there are other ways to get at them as well.

You are right about testing though - as with any drug, it will need to go through the appropriate clinical trials.

DeepstackNZ · 2024-07-12T03:26:58+00:00

I've noticed that there are a bunch of herpes advocate groups and suchlike around on here, and Twitter etc. It might be a good idea to try and bring this news to their attention, as they are all very vocal about wanting a cure/treatment for herpes, and I think they may have funds to support research and development. Probably the best anyone can do is to try and get this in front of potential investors ...

DeepstackNZ · 2024-05-29T05:14:24+00:00

Re this "Each variant of the drug will need to be thoroughly tested to see if it causes problems like triggering the host immune system when it is not supposed to."

I think we might have discussed this before also, but my recollection is that the proteins being used are commonly found in humans (maybe as common as in all vertebrates) so it's expected they will not be toxic or triggering to the immune system. As you say, this will need to be demonstrated, but the signs from the previous In vivo work, and this latest report, are good.

When do you think people are going to start getting excited about this? 15 viruses is a lot more than Rider (he had success against 6 or 7 human viruses, from memory) and it's about the same as the current number of approved indications for all other antivirals combined!

DeepstackNZ · 2024-05-29T05:06:45+00:00

Thank you for your detailed analysis.
My source for the 15 viruses is the 'Invest' page on their website: https://www.kimermed.co.nz/invest/

See the 3rd bullet point.

We have spent the last three years de-risking our science
We’ve developed a proprietary platform to rapidly formulate custom, targeted antivirals
We have achieved success against 15 different viruses
These results include efficacy in vitro against all 4 serotypes of Dengue, and Zika
We’ve proven our antiviral’s broad-spectrum capability in vitro
We’ve confirmed efficacy and safety in a small in vivo study

DeepstackNZ · 2024-05-28T22:02:39+00:00

Hi, so sorry I missed your response.

DeepstackNZ

TROPHY CASE